FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body
Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills. FibroBiologics is developing a different approach.The patent application
FibroBiologics filed a patent for technology that makes medicine inside your body. Instead of injections, it could deliver helpful medicines automatically over time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.